(266 days)
The MediAI-BA is designed to view and quantify bone age from 2D Posterior Anterior (PA) view of left-hand radiographs using deep learning techniques to aid in the analysis of bone age assessment of patients between 2 to 18 years old for pediatric radiologists. The results should not be relied upon alone by pediatric radiologists to make diagnostic decisions. The images shall be with left hand and wrist fully visible within the field of view, and shall be without any major bone destruction, deformity, fracture, excessive motion, or other major artifacts.
Limitations:
- This software is not intended for use in patients with growth disorders caused by congenital anomalies (e.g., Down syndrome, Noonan syndrome, congenital adrenal hyperplasia, methylmalonic acidemia, skeletal dysplasia, chronic renal disease, or prior long-term steroid exposure), as these conditions may cause complex skeletal changes beyond bone maturation.
- Images showing anatomical variations or notable abnormalities (e.g., bone tumors, sequelae of fractures, or congenital deformities) in the region required for interpretation are excluded from the intended use.
This AI-based software utilizes an internal algorithm that integrates global skeletal maturity features extracted from the whole hand radiograph with local skeletal maturity features derived from key Regions of Interest (ROIs). By synthesizing these skeletal maturity features, the software determines the accurate final bone age.
MediAI-BA provides an optional heatmap visualization that highlights regions contributing to the AI model output. The heatmap is intended only as supplementary, qualitative information to illustrate internal AI operations and is not intended for clinical interpretation, growth plate localization, or independent bone age assessment.
The confidence score graph is an internal model visualization intended only to illustrate the relative sharpness of the model's output distribution. It is not calibrated to clinical likelihood, has not been clinically validated, and is not intended to support diagnostic decisions or selection of a specific bone age.
Here's a breakdown of the acceptance criteria and study details for the MediAI-BA device, based on the provided FDA 510(k) clearance letter:
MediAI-BA Acceptance Criteria and Device Performance
1. Table of Acceptance Criteria and Reported Device Performance:
| Acceptance Criteria (Performance Metric) | Target (Implicit from "no significant bias" and "high consistency") | Reported Device Performance and Confidence Intervals |
|---|---|---|
| Deming Regression - Slope | Close to 1 (indicating no proportional bias) | 1.000 (95% CI: 0.989–1.002) |
| Deming Regression - Intercept | Close to 0 (indicating no systematic bias) | 0.08 (95% CI: −0.004–0.158) |
| Bland-Altman Analysis - 95% Limits of Agreement | Narrow range (demonstrating high consistency and agreement) | −0.66 (−1.96 SD) to 0.71 (+1.96 SD) |
| Frequency Distribution of Differences - Mean | Close to 0 (indicating negligible average difference) | 0.026 years |
| Frequency Distribution of Differences - Standard Deviation | Low (indicating high precision) | 0.3505 years |
| Frequency Distribution of Differences - Cases within 0.5 years | High percentage (indicating strong agreement for a large majority of cases) | 89% of all cases |
| Heatmap Consistency (SSIM) | ≥ 0.85 (for most evaluation cases under normal conditions) | Most of 30 evaluation cases met criteria under brightness adjustment and Gaussian noise. All 5 cases met criteria under rotation. |
| Heatmap Accuracy | Bone age changes observed when highlighted region is masked (indicating region's contribution to output) | Bone age changes observed in 27 out of 30 cases when the highlighted region of the heatmap was masked. |
Study Details
2. Sample size used for the test set and the data provenance:
- Sample Size: 600 cases.
- Data Provenance:
- Country of Origin: United States.
- Collection Sites: Five sites across multiple states and multiple clinical organizations.
- Retrospective/Prospective: Not explicitly stated, but the description of "collected from five sites" suggests a retrospective collection of existing images for this study. The phrase "None of the cases used in this study were utilized for training or development of the MediAI-BA model" reinforces that these were untouched test cases.
- Demographics: 50.0% males and 50.0% females. Racial/ethnic composition included White, Hispanic, Black, Asian & Pacific Islander, among others.
- Image Sources: X-ray scanner manufacturers included Samsung Electronics, Carestream Health, Kodak, Siemens, and Konica Minolta.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
- Number of Experts: Four evaluators.
- Qualifications of Experts: Not explicitly stated, but the context of "pediatric radiologists" in the Indications for Use and the assertion that the device "demonstrated performance comparable to bone age readings obtained by human evaluators using the GP atlas method" strongly imply that these evaluators were pediatric radiologists experienced in bone age assessment using the GP (Greulich and Pyle) atlas method.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set:
- The document states that ground truth was "established by four evaluators." It does not specify the exact adjudication method (e.g., whether it was consensus, average, or majority rule among the four).
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
- No, an MRMC comparative effectiveness study was not explicitly described. The study compared the device's standalone performance against the ground truth established by human evaluators. It did not evaluate how human readers' performance might improve when assisted by the AI.
6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done:
- Yes, a standalone performance study was done. The performance metrics (Deming regression, Bland-Altman, frequency distribution of differences) directly compare the "software's bone age analysis results" and "MediAI-BA outputs" against the "ground truth." This is a direct measurement of the algorithm's standalone performance.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc):
- The ground truth was established by "four evaluators" using the "GP atlas method." This indicates expert consensus/interpretation using a recognized standard (GP atlas).
8. The sample size for the training set:
- Not specified in the provided text. The document explicitly states that "None of the cases used in this study were utilized for training or development of the MediAI-BA model," but does not give details about the training set itself.
9. How the ground truth for the training set was established:
- Not specified in the provided text.
FDA 510(k) Clearance Letter - MediAI-BA
Page 1
U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov
Doc ID # 04017.08.02
CRESCOM Co., Ltd.
Rosa Han
Official Correspondent
801 Kinstower, 8 Seongnam-daero 331beon-gil
Seongnam-si, Gyeonggi-do 13558
Korea, South
Re: K250914
Trade/Device Name: MediAI-BA
Regulation Number: 21 CFR 892.2050
Regulation Name: Medical Image Management And Processing System
Regulatory Class: Class II
Product Code: QIH
Dated: November 7, 2025
Received: November 7, 2025
Dear Rosa Han:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"
December 18, 2025
Page 2
Rosa Han
Official Correspondent
801 Kinstower, 8 Seongnam-daero 331beon-gil
Seongnam-si, Gyeonggi-do 13558
Korea, South
Re: K250914
Trade/Device Name: MediAI-BA
Regulation Number: 21 CFR 892.2050
Regulation Name: Medical Image Management And Processing System
Regulatory Class: Class II
Product Code: QIH
Dated: November 7, 2025
Received: November 7, 2025
December 18, 2025
Dear Rosa Han:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"
K250914 - Rosa Han Page 2
(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-
Page 3
K250914 - Rosa Han Page 3
assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Jessica Lamb, Ph.D
Assistant Director
DHT8B: Division of Radiological Imaging
Devices and Electronic Products
OHT8: Office of Radiological Health
Office of Product Evaluation and Quality
Center for Devices and Radiological Health
Enclosure
Page 4
FORM FDA 3881 (6/20) Page 1 of 1 PSC Publishing Services (301) 443-6740 EF
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Indications for Use
Form Approved: OMB No. 0910-0120
Expiration Date: 06/30/2023
See PRA Statement below.
510(k) Number (if known)
K250914
Device Name
MediAI-BA
Indications for Use (Describe)
The MediAI-BA is designed to view and quantify bone age from 2D Posterior Anterior (PA) view of left-hand radiographs using deep learning techniques to aid in the analysis of bone age assessment of patients between 2 to 18 years old for pediatric radiologists. The results should not be relied upon alone by pediatric radiologists to make diagnostic decisions. The images shall be with left hand and wrist fully visible within the field of view, and shall be without any major bone destruction, deformity, fracture, excessive motion, or other major artifacts.
Limitations:
- This software is not intended for use in patients with growth disorders caused by congenital anomalies (e.g., Down syndrome, Noonan syndrome, congenital adrenal hyperplasia, methylmalonic acidemia, skeletal dysplasia, chronic renal disease, or prior long-term steroid exposure), as these conditions may cause complex skeletal changes beyond bone maturation.
- Images showing anatomical variations or notable abnormalities (e.g., bone tumors, sequelae of fractures, or congenital deformities) in the region required for interpretation are excluded from the intended use.
Type of Use (Select one or both, as applicable)
☒ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Form Approved: OMB No. 0910-0120
Expiration Date: 06/30/2023
See PRA Statement below.
Indications for Use
510(k) Number (if known)
K250914
Device Name
MediAI-BA
Indications for Use (Describe)
The MediAI-BA is designed to view and quantify bone age from 2D Posterior Anterior (PA) view of left-hand radiographs using deep learning techniques to aid in the analysis of bone age assessment of patients between 2 to 18 years old for pediatric radiologists. The results should not be relied upon alone by pediatric radiologists to make diagnostic decisions. The images shall be with left hand and wrist fully visible within the field of view, and shall be without any major bone destruction, deformity, fracture, excessive motion, or other major artifacts.
Limitations:
- This software is not intended for use in patients with growth disorders caused by congenital anomalies (e.g., Down syndrome, Noonan syndrome, congenital adrenal hyperplasia, methylmalonic acidemia, skeletal dysplasia, chronic renal disease, or prior long-term steroid exposure), as these conditions may cause complex skeletal changes beyond bone maturation.
- Images showing anatomical variations or notable abnormalities (e.g., bone tumors, sequelae of fractures, or congenital deformities) in the region required for interpretation are excluded from the intended use.
Type of Use (Select one or both, as applicable)
☒ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
FORM FDA 3881 (6/20) Page 1 of 1 PSC Publishing Services (301) 443-6740 EF
Page 5
510(k) Summary
1 / 5
This summary of 510(k) information is being submitted in accordance with requirements of 21 CFR Part 807.92.
- Date: March 18, 2025
- Submitter: CRESCOM Co., Ltd.
801 Kinstower, 8 Seongnam-daero 331beon-gil, Seongnam-si, Gyeonggi-do, 13558 Republic of Korea - Contact Person: Rosa Han
RA Specialist
rosa.han@carasolution.com
Tel. +82-10-4847-1022 - Device Information:
Device(Trade) Name: MediAI-BA
Classification Name: Automated Radiological Image Processing Software
Regulation Number: 21 CFR 892.2050
Regulation Name: Medical image management and processing system
Regulatory Class: Class II
Product Code: QIH - Predicate Device:
Manufacturer: Ever Fortune.AI Co., Ltd.
Trade/Device Name: EFAI BAPXR
510(k) Number: K234042
Regulation Name: Medical image management and processing system
Regulatory Number: 210 CFR 892.2050
Regulatory Class: Class II
Product Code: QIH
Identification of a Legally Marketed Predicate Device
MediAI-BA is substantially equivalent to the EFAI BAPXR marketed by Ever Fortune.AI Co., Ltd., 510(k) Premarket Notification Number K234042, FDA Product Code QIH.
General Description
This AI-based software utilizes an internal algorithm that integrates global skeletal maturity features extracted from the whole hand radiograph with local skeletal maturity features derived from key Regions of Interest (ROIs). By synthesizing these skeletal maturity features, the software determines the accurate final bone age.
MediAI-BA provides an optional heatmap visualization that highlights regions contributing to the AI model output. The heatmap is intended only as supplementary, qualitative information to illustrate internal AI operations and is not intended for clinical interpretation, growth plate localization, or independent bone age assessment.
The confidence score graph is an internal model visualization intended only to illustrate the relative sharpness of the model's output distribution. It is not calibrated to clinical likelihood, has not been clinically validated, and is not intended to support diagnostic decisions or selection of a specific bone
Page 6
510(k) Summary
This summary of 510(k) information is being submitted in accordance with requirements of 21 CFR Part 807.92.
-
Date: March 18, 2025
-
Submitter: CRESCOM Co., Ltd.
801 Kinstower, 8 Seongnam-daero 331beon-gil, Seongnam-si, Gyeonggi-do, 13558 Republic of Korea -
Contact Person: Rosa Han
RA Specialist
rosa.han@carasolution.com
Tel. +82-10-4847-1022 -
Device Information: Device(Trade) Name: MediAI-BA
Classification Name: Automated Radiological Image Processing Software
Regulation Number: 21 CFR 892.2050
Regulation Name: Medical image management and processing system
Regulatory Class: Class II
Product Code: QIH -
Predicate Device: Manufacturer: Ever Fortune.AI Co., Ltd.
Trade/Device Name: EFAI BAPXR
510(k) Number: K234042
Regulation Name: Medical image management and processing system
Regulatory Number: 210 CFR 892.2050
Regulatory Class: Class II
Product Code: QIH
Identification of a Legally Marketed Predicate Device
MediAI-BA is substantially equivalent to the EFAI BAPXR marketed by Ever Fortune.AI Co., Ltd., 510(k) Premarket Notification Number K234042, FDA Product Code QIH.
General Description
This AI-based software utilizes an internal algorithm that integrates global skeletal maturity features extracted from the whole hand radiograph with local skeletal maturity features derived from key Regions of Interest (ROIs). By synthesizing these skeletal maturity features, the software determines the accurate final bone age.
MediAI-BA provides an optional heatmap visualization that highlights regions contributing to the AI model output. The heatmap is intended only as supplementary, qualitative information to illustrate internal AI operations and is not intended for clinical interpretation, growth plate localization, or independent bone age assessment.
The confidence score graph is an internal model visualization intended only to illustrate the relative sharpness of the model's output distribution. It is not calibrated to clinical likelihood, has not been clinically validated, and is not intended to support diagnostic decisions or selection of a specific bone
1 / 5
age.
Indication for Use
The MediAI-BA is designed to view and quantify bone age from 2D Posterior Anterior (PA) view of left-hand radiographs using deep learning techniques to aid in the analysis of bone age assessment of patients between 2 to 18 years old for pediatric radiologists. The results should not be relied upon alone by pediatric radiologists to make diagnostic decisions. The images shall be with left hand and wrist fully visible within the field of view, and shall be without any major bone destruction, deformity, fracture, excessive motion, or other major artifacts.
Limitations:
- This software is not intended for use in patients with growth disorders caused by congenital anomalies (e.g., Down syndrome, Noonan syndrome, congenital adrenal hyperplasia, methylmalonic acidemia, skeletal dysplasia, chronic renal disease, or prior long-term steroid exposure), as these conditions may cause complex skeletal changes beyond bone maturation.
- Images showing anatomical variations or notable abnormalities (e.g., bone tumors, sequelae of fractures, or congenital deformities) in the region required for interpretation are excluded from the intended use.
Comparison of Technological Characteristics
| Subject Device | Predicate Device (K234042) |
|---|---|
| Device(Trade) Name | MediAI-BA |
| Classification Name | Automated Radiological Image Processing Software |
| Product Code | QIH |
| Regulation Number | 21 CFR 892.2050 |
| Regulatory Class | Class II |
| Intended Use/Indication for Use | The MediAI-BA is designed to view and quantify bone age from 2D Posterior Anterior (PA) view of left-hand radiographs using deep learning techniques to aid in the analysis of bone age assessment of patients between 2 to 18 years old for pediatric radiologists. The results should not be relied upon alone by pediatric radiologists to make diagnostic decisions. The images shall be with left hand and wrist fully visible within the field of view, and shall be without any major bone destruction, deformity, fracture, excessive motion, or other major artifacts.Limitations:– This software is not intended for use in patients with growth disorders caused by congenital anomalies (e.g., |
Page 7
2 / 5
Down syndrome, Noonan syndrome, congenital adrenal hyperplasia, methylmalonic acidemia, skeletal dysplasia, chronic renal disease, or prior long-term steroid exposure), as these conditions may cause complex skeletal changes beyond bone maturation.
– Images showing anatomical variations or notable abnormalities (e.g., bone tumors, sequelae of fractures, or congenital deformities) in the region required for interpretation are excluded from the intended use.
| Subject Device | Predicate Device (K234042) | |
|---|---|---|
| Environment of Use | Healthcare facility/Hospital | Healthcare facility/Hospital |
| Intended User | Pediatric radiologist | Pediatric radiologist |
| Clinical Condition | Bone age assessment | Bone age assessment |
| Image Input | Complies with DICOM standard | Complies with DICOM standard |
| Scan Type | X-ray | X-ray |
| Anatomical Area | Left hand and wrist | Left hand and wrist |
| Image Display Mode | Static | Static |
| Artificial Intelligence Algorithm | Yes | Yes |
| Image Navigation and Manipulation Tools | No | No |
| 2D Image Review | No | No |
| Manual Landmark Placement | No | No |
| Semiautomatic Landmark Placement | No | No |
| Quantitative Analysis | Bone age assessment (years) | Bone age assessment (years) |
| Report Creation | Yes | No |
The MediAI-BA and the predicate device EFAI BAPXR (K234042) are both AI-based automated radiological image processing software designed to assist pediatric radiologists in bone age assessment using 2D Posterior-Anterior (PA) X-ray images of the left hand and wrist.
Both devices employ deep learning algorithms to analyze input images and generate bone age estimates. They operate in healthcare facilities and hospitals, are intended for pediatric radiologists,
3 / 5
and are classified under 21 CFR 892.2050, Product Code QIH, Class II.
Brief Summary of Performance Testing
CRESCOM conducted an independent performance evaluation study of MediAI-BA.
The test dataset consisted of 600 cases aged 2–18 years, collected from five sites across multiple states and multiple clinical organizations in the United States. The study population included 50.0% males and 50.0% females, and the racial/ethnic composition comprised White, Hispanic, Black, Asian & Pacific Islander, among others.
The X-ray scanner manufacturers used for the images included Samsung Electronics, Carestream Health, Kodak, Siemens, and Konica Minolta. (None of the cases used in this study were utilized for training or development of the MediAI-BA model.)
By comparing the software's bone age analysis results with the ground truth established by four evaluators, MediAI-BA was confirmed to meet all of the predefined performance criteria described below.
- In the Deming regression analysis, the slope was 1.000 (95% CI: 0.989–1.002) and the intercept was 0.08 (95% CI: −0.004–0.158), which is close to zero. The confidence intervals included 1 for the slope and 0 for the intercept, indicating no significant proportional or systematic bias between the software and the reference standard measurements.
- In the Bland–Altman analysis, the 95% limits of agreement for bone age assessment between the ground truth and MediAI-BA outputs ranged from −0.66 (−1.96 SD) to 0.71 (+1.96 SD), demonstrating high consistency and agreement.
- When the frequency distribution (histogram) of differences between MediAI-BA bone age measurements and the reference standard was analyzed with a bin width of 0.25 years, the mean difference was 0.026 years and the standard deviation was 0.3505 years, with most cases clustered near zero. Additionally, 89% of all cases demonstrated a difference of less than 0.5 years between the ground truth values and the software output.
Therefore, the automatic AI-based bone age assessment software, MediAI-BA, demonstrated performance comparable to bone age readings obtained by human evaluators using the GP atlas method.
We evaluated the consistency and accuracy of the heatmaps provided as visual evidence for MediAI-BA.
Consistency tests showed that most of the 30 evaluation cases met the predefined criterion (SSIM ≥ 0.85). All cases met the criteria under brightness adjustment and Gaussian noise conditions, and all five cases under rotation conditions also met the criteria. While some cases exhibited low SSIM scores under extreme conditions, such situations are considered highly unlikely to occur in real-world clinical imaging settings.
Accuracy tests revealed that bone age changes were observed in 27 of the 30 cases when the highlighted region of the heatmap was masked. In the remaining three cases, similar bone age values were observed in other regions even when a specific region was masked, indicating that masking did not significantly impact the evaluation results.
In conclusion, MediAI-BA's heatmap function demonstrated reliable visual consistency and accuracy across most test cases. Therefore, heatmaps can be used as a supplementary reference for understanding the interpretation of AI analysis results.
Page 8
4 / 5
and are classified under 21 CFR 892.2050, Product Code QIH, Class II.
Brief Summary of Performance Testing
CRESCOM conducted an independent performance evaluation study of MediAI-BA.
The test dataset consisted of 600 cases aged 2–18 years, collected from five sites across multiple states and multiple clinical organizations in the United States. The study population included 50.0% males and 50.0% females, and the racial/ethnic composition comprised White, Hispanic, Black, Asian & Pacific Islander, among others.
The X-ray scanner manufacturers used for the images included Samsung Electronics, Carestream Health, Kodak, Siemens, and Konica Minolta. (None of the cases used in this study were utilized for training or development of the MediAI-BA model.)
By comparing the software's bone age analysis results with the ground truth established by four evaluators, MediAI-BA was confirmed to meet all of the predefined performance criteria described below.
- In the Deming regression analysis, the slope was 1.000 (95% CI: 0.989–1.002) and the intercept was 0.08 (95% CI: −0.004–0.158), which is close to zero. The confidence intervals included 1 for the slope and 0 for the intercept, indicating no significant proportional or systematic bias between the software and the reference standard measurements.
- In the Bland–Altman analysis, the 95% limits of agreement for bone age assessment between the ground truth and MediAI-BA outputs ranged from −0.66 (−1.96 SD) to 0.71 (+1.96 SD), demonstrating high consistency and agreement.
- When the frequency distribution (histogram) of differences between MediAI-BA bone age measurements and the reference standard was analyzed with a bin width of 0.25 years, the mean difference was 0.026 years and the standard deviation was 0.3505 years, with most cases clustered near zero. Additionally, 89% of all cases demonstrated a difference of less than 0.5 years between the ground truth values and the software output.
Therefore, the automatic AI-based bone age assessment software, MediAI-BA, demonstrated performance comparable to bone age readings obtained by human evaluators using the GP atlas method.
We evaluated the consistency and accuracy of the heatmaps provided as visual evidence for MediAI-BA.
Consistency tests showed that most of the 30 evaluation cases met the predefined criterion (SSIM ≥ 0.85). All cases met the criteria under brightness adjustment and Gaussian noise conditions, and all five cases under rotation conditions also met the criteria. While some cases exhibited low SSIM scores under extreme conditions, such situations are considered highly unlikely to occur in real-world clinical imaging settings.
Accuracy tests revealed that bone age changes were observed in 27 of the 30 cases when the highlighted region of the heatmap was masked. In the remaining three cases, similar bone age values were observed in other regions even when a specific region was masked, indicating that masking did not significantly impact the evaluation results.
In conclusion, MediAI-BA's heatmap function demonstrated reliable visual consistency and accuracy across most test cases. Therefore, heatmaps can be used as a supplementary reference for understanding the interpretation of AI analysis results.
Page 9
5 / 5
Conclusion
Based on the nonclinical and clinical evidence, MediAI-BA is substantially equivalent to the legally marketed predicate device in terms of safety, effectiveness, and performance. The device introduces no new risks and demonstrates comparable functionality and optimized workflow efficiency in bone age assessment, supporting its suitability for regulatory clearance.
N/A